Department of Basic Sciences , California Northstate University College of Medicine , Elkgrove , California 95757 , United States.
Novartis Institutes for Biomedical Research , Basel CH-4057 , Switzerland.
J Nat Prod. 2018 Apr 27;81(4):811-817. doi: 10.1021/acs.jnatprod.7b00893. Epub 2018 Apr 10.
The drimane sesquiterpenoids drimenin, cinnamolide, dendocarbin A, and polygodial were purified from the Canelo tree ( Drimys winteri) and chemically characterized by spectroscopic methods. The pharmacological activity of these natural compounds were determined on hα4β2, hα3β4, and hα7 nicotinic acetylcholine receptors (AChRs) by Ca influx measurements. The results established that drimane sesquiterpenoids inhibit AChRs with the following selectivity: hα4β2 > hα3β4 > hα7. In the case of hα4β2 AChRs, the following potency rank order was determined (IC's in μM): drimenin (0.97 ± 0.35) > cinnamolide (1.57 ± 0.36) > polygodial (62.5 ± 19.9) ≫ dendocarbin A (no activity). To determine putative structural features underlying the differences in inhibitory potency at hα4β2 AChRs, additional structure-activity relationship and molecular docking experiments were performed. The Ca influx and structural results supported a noncompetitive mechanism of inhibition, where drimenin interacted with luminal and nonluminal (TMD-β2 intrasubunit) sites. The structure-activity relationship results, i.e., the lower the ligand polarity, the higher the inhibitory potency, supported the nonluminal interaction. Ligand binding to both sites might inhibit the hα4β2 AChR by a cooperative mechanism, as shown experimentally ( n > 1). Drimenin could be used as a molecular scaffold for the development of more potent inhibitors with higher selectivity for the hα4β2 AChR.
从 Canelo 树( Drimys winteri)中分离出的倍半萜 drimenin、肉桂醇、dendocarbin A 和聚戈醛,并用光谱方法对其进行了化学表征。通过 Ca2+内流测定法,测定了这些天然化合物对 hα4β2、hα3β4 和 hα7 烟碱型乙酰胆碱受体(AChRs)的药理活性。结果表明,倍半萜类化合物对 AChRs 的抑制作用具有以下选择性:hα4β2>hα3β4>hα7。在 hα4β2 AChRs 的情况下,确定了以下效力顺序(IC 在μM 时):drimenin(0.97±0.35)>肉桂醇(1.57±0.36)>聚戈醛(62.5±19.9)> dendocarbin A(无活性)。为了确定 hα4β2 AChRs 抑制效力差异的潜在结构特征,进行了额外的构效关系和分子对接实验。Ca2+内流和结构结果支持非竞争性抑制机制,其中 drimenin 与腔内侧和非腔内侧(TMD-β2 亚基内)结合。构效关系结果,即配体极性越低,抑制效力越高,支持非腔内侧相互作用。配体与两个部位的结合可能通过实验证明的协同机制抑制 hα4β2 AChR(n>1)。Drimenin 可用作开发具有更高 hα4β2 AChR 选择性的更有效抑制剂的分子支架。